ライフサイエンスコーパス: muscle disorder

1 ing renal, thyroid and kidney dysfunction or muscle disorder.

2 hy (HCM) is a common, serious, genetic heart muscle disorder.

3 l arthrogryposis-1 (DA-1), a severe skeletal muscle disorder.

4 veloping more effective therapeutic ASOs for muscle disorders.

5 emerged as one of the most common congenital muscle disorders.

6 elopathies as putative aetiologies of smooth muscle disorders.

7 eutic approach for a variety of degenerative muscle disorders.

8 based therapies in DMD and potentially other muscle disorders.

9 ciple for future hPSC-based cell therapy for muscle disorders.

10 he relevance of splicing-related proteins in muscle disorders.

11 tractile properties are hallmarks of various muscle disorders.

12 ve skeletal muscle formation in degenerative muscle disorders.

13 the diagnosis, management, and treatment of muscle disorders.

14 tal muscle mass in many acquired and genetic muscle disorders.

15 veness of gene- and cell-based therapies for muscle disorders.

16 tential intracellular therapeutic target for muscle disorders.

17 omyosin, as needed in therapeutic design for muscle disorders.

18 new and personalized treatments for skeletal muscle disorders.

19 7 may be an important therapeutic target for muscle disorders.

20 tly being pursued as therapeutic options for muscle disorders.

21 promises for the treatment of many forms of muscle disorders.

22 and neuropsychiatric diseases, and skeletal muscle disorders.

23 sed this treatment strategy for pathological muscle disorders.

24 aging syndromes, lipodystrophy, and striated muscle disorders.

25 wasting in chronic diseases and degenerative muscle disorders.

26 fflicted with ischemic and nonischemic heart muscle disorders.

27 se channels are known to cause several human muscle disorders.

28 c population included patients with 12 other muscle disorders.

29 atments for muscle weakness in DMD and other muscle disorders.

30 ential therapeutic approach for degenerative muscle disorders.

31 tment of strabismus, nystagmus, or other eye muscle disorders.

32 oving regeneration in diverse and burdensome muscle disorders.

33 on subtype of childhood onset non-dystrophic muscle disorders.

34 s in transcription factors cause a number of muscle disorders.

35 hem attractive models for studying mammalian muscle disorders.

36 of genetic therapy for DMD, as well as other muscle disorders.

37 biopsies from patients with undiagnosed rare muscle disorders(6,9), and cultured fibroblasts from pat

38 ons learned from systemic genetic therapy of muscle disorders also should have implications for other

39 roderma myopathy is a heterogeneous group of muscle disorders among patients with underlying sclerode

40 fective therapeutic drug against involuntary muscle disorders and for pain management.

41 sing the underlying genetic causes of smooth muscle disorders and offer a potential transformative tr

42 applied to evaluate a wide range of skeletal muscle disorders and protein targets.

43 of clinical symptoms that include nerve and muscle disorders and red cell acanthocytosis.

44 everal ongoing clinical trials for different muscle disorders and the advances in the understanding o

45 ts a promising strategy for the treatment of muscle disorders and type 2 diabetes.

46 were 8 subjects who were being evaluated for muscle disorders and who were not diagnosed as having ju

47 yosin SRX-DRX states is perturbed in various muscle disorders, and myosin SRX-DRX states have become

48 The primary muscle disorders are a diverse group of diseases caused

49 s causing FPLD, in contrast to those causing muscle disorders, are tightly clustered within the C-ter

50 auses nemaline myopathy, a lethal congenital muscle disorder associated with aberrant myofiber struct

51 -epimerase/ManNAc kinase) myopathy is a rare muscle disorder associated with aging and is related to

52 have DMD gene mutations but may have another muscle disorder associated with elevated neonatal creati

53 41 (KLHL41) cause nemaline myopathy, a fatal muscle disorder associated with sarcomere disarray.

54 ic right ventricular cardiomyopathy, a heart muscle disorder associated with ventricular arrhythmias,

55 and genetically heterogeneous group of heart muscle disorders associated with high morbidity and mort

56 Thus, aberrant SOCE could contribute to muscle disorders associated with loss of TRIC-A.

57 (NF-kappaB) is involved in multiple skeletal muscle disorders, but how it functions in differentiatio

58 Fibrosis is a key pathological feature in muscle disorders, but its quantification mainly relies o

59 Infantile Pompe disease is a fatal genetic muscle disorder caused by a deficiency of acid alpha-glu

60 uchenne Muscular Dystrophy (DMD) is a severe muscle disorder caused by lack of dystrophin.

61 rage myopathy (MSM) is a congenital skeletal muscle disorder caused by missense mutations in the beta

62 ongenita is a temperature-sensitive skeletal muscle disorder caused by missense mutations that occur

63 nne muscular dystrophy (DMD), a degenerative muscle disorder caused by mutations in the dystrophin ge

64 muscular dystrophy (DMD) is a lethal genetic muscle disorder caused by recessive mutations in dystrop

65 (HyperKPP) is an autosomal dominant skeletal muscle disorder caused by single mutations in the SCN4A

66 arcotubular myopathy are hereditary skeletal muscle disorders caused by mutations in TRIM32.

67 uchenne Muscular Dystrophy (DMD) is a lethal muscle disorder, caused by mutations in the DMD gene and

68 (DMD) is the most common and lethal genetic muscle disorder, caused by recessive mutations in the dy

69 ies for patients with congenital myopathies, muscle disorders causing poor quality of life of affecte

70 Dilated cardiomyopathy (DCM) is a heart muscle disorder characterized by atrial and ventricular

71 Duchenne muscular dystrophy (DMD) is a fatal muscle disorder characterized by cycles of degeneration

72 ve cardiomyopathy (RCM) is an uncommon heart muscle disorder characterized by impaired filling of the

73 Nemaline myopathy (NM) is a genetic muscle disorder characterized by muscle dysfunction and

74 NEB) cause typical nemaline myopathy (NM), a muscle disorder characterized by muscle weakness with li

75 c cardiomyopathy (ACM) is an inherited heart muscle disorder characterized by myocardial fibrofatty r

76 Inclusion body myopathy is a progressive muscle disorder characterized by nuclear and cytoplasmic

77 (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing diff

78 y myopathies (IMs) are debilitating skeletal muscle disorders characterized by common pathological ev

79 cally and genetically heterogeneous group of muscle disorders characterized by congenital or early-on

80 ibilities for the treatment of many forms of muscle disorders characterized by impaired regeneration

81 phies (MDs) comprise a group of degenerative muscle disorders characterized by progressive muscle was

82 ystrophin gene cause the severe degenerative muscle disorder, Duchenne muscular dystrophy (DMD).

83 physiologic approach to certain drug-induced muscle disorders, especially those caused by the lipid-l

84 next-generation vectors for gene therapy of muscle disorders, given the relatively modest advances i

85 Inclusion body myositis, the most common muscle disorder in the elderly, is partly characterized

86 f inflammatory myopathies and those of other muscle disorders, in particular, the genetic muscular dy

87 riteria, the most common immune inflammatory muscle disorders include Dermatomyositis (DM), Polymyosi

88 ous exercise and in a spectrum of congenital muscle disorders including malignant hyperthermia.

89 ia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle

90 foundation for future research investigating muscle disorders involving sarcomeric components.

91 ic dystrophy (DM), the most common inherited muscle disorder, is caused by a CTG expansion in the 3"-

92 ispositioned nuclei are correlated with many muscle disorders, it is not known whether this common ph

93 otonia are three autosomal dominant skeletal muscle disorders linked to the SCN4A gene encoding the a

94 ported muscle symptoms, clinically confirmed muscle disorders, liver dysfunction, renal insufficiency

95 The severity of the muscle disorder may vary from trivial myalgias or elevat

96 ide channel are associated with the skeletal muscle disorder myotonia congenita.

97 channels have been linked to the hereditary muscle disorder myotonia congenita.

98 lated cardiomyopathy (DCM) is a common heart muscle disorder of nonischemic etiology associated with

99 to describe a large family of complex heart muscle disorders of diverse aetiology and pathophysiolog

100 to be important contributors to neuronal and muscle disorders of excitability.

101 e highly prevalent and economically damaging muscle disorders of modern commercial broiler chickens c

102 diseases that affect nonsphincteric gastric muscle, disorders of the extrinsic neural control, and p

103 ere not associated with clinically confirmed muscle disorders or diabetes.

104 in RyRs are associated with severe skeletal muscle disorders or triggered cardiac arrhythmias.

105 screening programs but is found in inherited muscle disorders other than DMD.

106 mogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, p

107 Nemaline myopathy (NM) is a rare congenital muscle disorder primarily affecting skeletal muscles tha

108 ne receptor (RYR1) result in a wide range of muscle disorders referred to as RYR1-related myopathies

109 lar cardiomyopathy (ARVC) is a primary heart muscle disorder resulting from desmosomal protein mutati

110 causes such as celiac disease, thyroid, and muscle disorders should be considered in the differentia

111 ty of cTnT in patients with various skeletal muscle disorders (SMDs).

112 Given this channel's involvement in other muscle disorders such as paramyotonia congenita and hype

113 al in treating nitric oxide-dependent smooth muscle disorders, such as erectile dysfunction.

114 increased prevalence of skeletal and cardiac muscle disorders, such as sarcopenia and cardiac infarct

115 rhythmogenic cardiomyopathy (ACM) is a heart muscle disorder that cannot be explained by ischemic, hy

116 opathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, a

117 ic paralysis (HypoPP) is a familial skeletal muscle disorder that presents with recurrent episodes of

118 lar dystrophy is a general term encompassing muscle disorders that cause weakness and wasting, typica

119 ic paralyses are a diverse group of skeletal muscle disorders that share a common pathophysiological

120 th nemaline myopathy (NM), a severe skeletal muscle disorder; this residue is conserved among Lmod an

121 se either a cardiac or a congenital skeletal muscle disorder through different modes of inheritance.

122 range from inherited cardiac arrhythmias, to muscle disorders, to forms of diabetes.

123 source of cells for the treatment of genetic muscle disorders, trauma-induced muscle damage and age-r

124 d genetically heterogeneous group of primary muscle disorders where weakness and atrophy are restrict

125 tions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascu

126 singly used to assess disease involvement in muscle disorders, while imaging techniques for assessmen

127 eterogeneous group of genetically determined muscle disorders with a primary or predominant involveme

128 Consequently, the treatment of muscle disorders with mesoangioblasts should take into c

129 comprise a heterogeneous group of heritable muscle disorders with often difficult to interpret muscl

130 stem cell-based therapies to treat skeletal muscle disorders, with a special emphasis on muscular dy

131 NaV1.4 give rise to a heterogeneous group of muscle disorders, with gain-of-function defects causing